清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pts) with newly diagnosed advanced ovarian cancer (aOC) (1266)

医学 耐受性 不利影响 内科学 安慰剂 卵巢癌 临床终点 肿瘤科 泌尿科 临床试验 癌症 病理 替代医学
作者
Jianqing Zhu,Lingying Wu,Rutie Yin,Jing Wang,Lingya Pan,Beihua Kong,Hong Zheng,Ji‐Long Liu,Xiaohua Wu,Li Wang,Yi Huang,Ke Wang,Dongling Zou,Hongqin Zhao,Chunyan Wang,Weiguo Lü,Lin An,Ge Lou,Guiling Li,Pengpeng Qu,Hongying Yang,Yu Zhang,Xiaoa Zhen,Wenzhao Hang,Jianmei Hou
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:176: S168-S169
标识
DOI:10.1016/j.ygyno.2023.06.175
摘要

Progression-free survival (PFS) was significantly extended with niraparib maintenance treatment versus placebo in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) in the phase III PRIME study (NCT03709316), but 40.4% of pts. required dose modifications due to treatment-emergent adverse events (TEAEs) and the impact of these modifications is still unknown. This study aimed to compare the efficacy of niraparib with TEAE-caused dose reductions or no dose reductions in the first-line maintenance setting. This was a post hoc analysis of niraparib-treated pts. from PRIME, which randomized adult pts. with newly diagnosed aOC 2:1 to receive niraparib or placebo after a response to first-line platinum-based chemotherapy. The starting daily dose was 200 mg for pts. with a body weight of <77 kg and/or a platelet count of <150,000/μL at baseline and 300 mg for all others. With no dose interruption or reduction in the first two cycles, the daily dose for pts. starting at 200 mg could be increased to 300 mg at the investigators' discretion. The daily dose could be reduced stepwise by 100 mg to manage treatment-related adverse events, and if tolerability improved following reductions, it could be escalated stepwise by 100 mg without exceeding the initial level. The primary endpoint was PFS (BICR). Subgroups comprised niraparib-treated pts. who experienced TEAE-caused dose reductions or had no dose reductions. Dose reductions included reductions following interruptions as specified in the protocol and direct reductions. Of 255 niraparib-treated pts., 103 (40.4%) experienced dose reductions, including direct reductions in 6, due to TEAEs (Fig. 1A), most commonly, platelet count decreased (24.3%), anemia (10.2%), and neutrophil count decreased (9.8%). The median time from randomization to first dose interruption or direct reduction, whichever came earlier, due to TEAEs was 29 days (range: 8–397), and the median time from first dose interruption to the resumption of treatment was 15.5 days (range: 1–28). The distribution of daily dose levels at each cycle is presented in Fig. 1B. Key baseline characteristics were overall balanced between subgroups with TEAE-caused reductions and no reductions. In pts. with TEAE-caused reductions and no reductions, the median total exposure time was 21.9 (range: 1.1–37.8) and 17.5 (range: 0.1–38.5) months (mo), and median relative dose intensity (average actual daily dose/planned starting daily dose) was 58% (range: 26%–106%) and 100% (range: 98%–147%), respectively. Median PFS (95% CI) with TEAE-caused reductions versus no reductions was 27.6 (16.6-not estimable [NE]) versus 24.8 (16.6–NE) mo (HR: 0.89, 95% CI: 0.61–1.30), with not reached versus 24.8 mo in pts. carrying germline BRCA mutations (HR: 0.60, 95% CI: 0.29–1.25) and 16.6 versus 24.8 mo in pts. carrying no germline BRCA mutations (HR: 1.02, 95% CI: 0.66–1.60). The efficacy of niraparib maintenance treatment with an individualized starting dose in pts. with newly diagnosed aOC was not impacted by dose modifications due to TEAEs, regardless of germline BRCA mutation status.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
10秒前
酷波er的应助被初景采纳,获得10
12秒前
学霸业的应助被369ninja采纳,获得10
13秒前
沉溪完成签到,获得积分10
16秒前
着急的冷珍完成签到,获得积分10
21秒前
赘婿的应助被科研通管家采纳,获得10
29秒前
奔跑的应助被科研通管家采纳,获得10
29秒前
DW的应助被369ninja采纳,获得10
30秒前
34秒前
43秒前
学霸业的应助被369ninja采纳,获得10
47秒前
五月完成签到,获得积分10
49秒前
初景发布了新的文献求助10
50秒前
甜美的冬天完成签到,获得积分10
55秒前
59秒前
情怀的应助被369ninja采纳,获得10
1分钟前
大气翠风完成签到,获得积分10
1分钟前
1分钟前
Perse发布了新的文献求助10
1分钟前
orixero的应助被369ninja采纳,获得10
1分钟前
1分钟前
香蕉乐曲完成签到,获得积分10
1分钟前
1分钟前
美好的飞兰完成签到,获得积分10
1分钟前
爆米花的应助被369ninja采纳,获得10
1分钟前
2分钟前
JUN完成签到,获得积分10
2分钟前
瞿人雄完成签到,获得积分10
2分钟前
没心没肺完成签到,获得积分10
2分钟前
Jasper的应助被科研通管家采纳,获得10
2分钟前
2分钟前
丘比特的应助被科研通管家采纳,获得10
2分钟前
上官若男的应助被科研通管家采纳,获得10
2分钟前
Ava的应助被科研通管家采纳,获得10
2分钟前
大意的之柔完成签到,获得积分10
2分钟前
2分钟前
2分钟前
369ninja发布了新的文献求助10
2分钟前
可靠往事完成签到,获得积分10
2分钟前
自由的梦山完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179961
求助须知:如何正确求助?哪些是违规求助? 9570183
关于积分的说明 21808480
捐赠科研通 7775832
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557373
邀请新用户注册赠送积分活动 2478958